Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN; ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuri ...
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.
Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, opportunities ...
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Adicet Bio (ACET) to $9 from $4 and keeps a Buy rating on the shares. The ...
Pregnancy increases the risk of flare in patients with SLE and is associated with excess fetal morbidity and mortality.1 The ...
An estimated 50% of patients with SLE will develop lupus nephritis in their lifetime, with people of African descent more ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...
Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence. Kennedy's reign has been ...
The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...
Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral ...
In a recent interview, clips of which have gone viral on social media, Abbasi confirmed that he was diagnosed with nephritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback